Healthy Source: Application for market approval of Lekanqita monoclonal antibody injection has been accepted.

Health Genesis announced that the domestic production drug registration and market approval application for the "Lecanixitan Injection" of its holding subsidiary Lijia Single Antibody has been accepted by the National Medical Products Administration. This drug is the first domestically developed and globally second-in-class innovative IL-17A/F dual-target inhibitor, suitable for adult patients with moderate to severe plaque psoriasis who are suitable for systemic treatment or phototherapy. As of the disclosure date of the announcement, the cumulative research and development expenses directly invested in the drug are approximately 204 million yuan. According to IQVIA sample statistical estimated data, the domestic terminal sales amount of IL-17A and IL-17RA single-target drugs in 2024 is estimated to be 2.833 billion yuan.